BREED Based De Novo Hybridization Approach: Generating Novel T790M/C797S-EGFR Tyrosine Kinase Inhibitors to Overcome the Problem of Mutation and Resistance in Non Small Cell Lung Cancer (NSCLC).

Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. However, EGFR tertiary Cys...